During clinical trials where the anti-PD-L1 effect was tested against canine melanomas, good clinical responses were obtained in cytoplasmatic stained tumors and no association was noted between staining pattern (membranous or cytoplasmatic) and clinical response [45,48,51]. The gene discussed is CD274; the disease is melanoma.